Skip to main content
SpringerLink
Log in

m6A-related bioinformatics analysis and functional characterization reveals that METTL3-mediated NPC1L1 mRNA hypermethylation facilitates progression of atherosclerosis via inactivation of the MAPK pathway

  • Original Research Paper
  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

Objective

Accumulating evidence has demonstrated that N6-methyladenosine (m6A) plays important roles in many major diseases, including atherosclerosis (AS). In the present study, we aimed to explore the transcriptomic m6A landscape of endothelial function-associated genes and identify potential regulators in AS progression.

Methods

The GEO data (GSE142386) from MeRIP-seq in human umbilical vein endothelial cells (HUVECs) with METTL3 knocked down or not were analyzed. RNA-seq was performed to identify differences in gene expression. Gene ontology (GO) functional and Kyoto encyclopedia of genes and genomes (KEGG) pathway analyses were conducted to evaluate the potential functions of the differentially expressed genes. MeRIP-qPCR was used to measure the m6A and mRNA levels of the top 8 downregulated genes, and NPC1L1 was selected as the candidate gene. Oxidized low-density lipoprotein (ox-LDL) was used to stimulate HUVECs, and METTL3 or NPC1L1 was silenced in ox-LDL-treated cells. And Transwell, ELISA, and cell apoptosis assays were performed to assess cell functional injury. ApoE-/- mice were fed with high-fat diet for 8 weeks to establish an AS model, and adenovirus-mediated NPC1L1 shRNA or NC shRNA was injected into the mice through the tail vein. Mouse aortic tissue damage and plaque deposition were evaluated by H&E, Oil Red O, and TUNEL staining.

Results

One hundred and ninety-four hypermethylated m6A peaks and 222 hypomethylated peaks were detected in response to knockdown of METTL3. Genes with altered m6A peaks were significantly involved in the histone modification, enzyme activity, and formation of multiple complexes and were predominantly enriched in the MAPK pathway. NPC1L1 was a most significantly downregulated transcript in response to knockdown of METTL3. Moreover, knockdown of NPC1L1 or de-m6A (METTL3 knockdown)-mediated downregulation of NPC1L1 could improve ox-LDL-induced dysfunction of HUVECs in vitro and high-fat diet-induced atherosclerotic plaque in vivo, which was associated with the inactivation of the MAPK pathway.

Conclusion

METTL3-mediated NPC1L1 mRNA hypermethylation facilitates AS progression by regulating the MAPK pathway, and NPC1L1 may be a novel target for the treatment of AS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Data availability

The datasets used during the present study are available from the corresponding author upon reasonable request.

References

  1. Libby P. Inflammation in atherosclerosis—no longer a theory. Clin Chem. 2021;67(1):131–42.

    Article  PubMed  Google Scholar 

  2. Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol. 2007;49(25):2379–93.

    Article  CAS  PubMed  Google Scholar 

  3. Li X, Zhou J, Dou Y, Shi Y, Wang Y, Hong J, et al. The protective effects of angelica organic acid against ox-LDL-induced autophagy dysfunction of HUVECs. BMC Complement Med and Ther. 2020;20(1):1–13.

    Article  Google Scholar 

  4. Shah PK. Inflammation, infection and atherosclerosis. Trends Cardiovasc Med. 2019;29(8):468–72.

    Article  CAS  PubMed  Google Scholar 

  5. Campbell LA, Rosenfeld ME. Infection and atherosclerosis development. Arch Med Res. 2015;46(5):339–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Chen L, Zhao Y, Huang L, Li Y, Xu H, Yang C, et al. The potential roles of RNA N6-methyladenosine in atherosclerosis. Eur Rev Med Pharmacol Sci. 2022;26(4):1075–83.

    PubMed  Google Scholar 

  7. Liu L, Wang J, Sun G, Wu Q, Ma J, Zhang X, et al. m6A mRNA methylation regulates CTNNB1 to promote the proliferation of hepatoblastoma. Mol Cancer. 2019;18(1):1–13.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Zhang X, Li X, Jia H, An G, Ni J. The m(6)A methyltransferase METTL3 modifies PGC-1alpha mRNA promoting mitochondrial dysfunction and oxLDL-induced inflammation in monocytes. J Biol Chem. 2021. https://doi.org/10.1016/j.jbc.2021.101058.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Zhang C, Fu J, Zhou Y. A review in research progress concerning m6a methylation and immunoregulation. Front Immunol. 2019;10:922. https://doi.org/10.3389/fimmu.2019.00922.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Quiles-Jiménez A, Gregersen I, de Sousa MML, Abbas A, Kong XY, Alseth I, et al. N6-methyladenosine in RNA of atherosclerotic plaques: an epitranscriptomic signature of human carotid atherosclerosis. Biochem Biophys Res Commun. 2020;533(4):631–7.

    Article  PubMed  Google Scholar 

  11. Li Z, Xu Q, Huangfu N, Chen X, Zhu J. Mettl3 promotes oxLDL-mediated inflammation through activating STAT1 signaling. J Clin Lab Anal. 2022. https://doi.org/10.1002/jcla.24019.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Zhang B, Han L, Tang Y, Zhang G, Fan X, Zhang J, et al. METTL14 regulates M6A methylation-modified primary miR-19a to promote cardiovascular endothelial cell proliferation and invasion. Eur Rev Med Pharmacol Sci. 2020;24(12):7015–23.

    PubMed  Google Scholar 

  13. Chamorro-Jorganes A, Sweaad WK, Katare R, Besnier M, Anwar M, Beazley-Long N, et al. METTL3 regulates angiogenesis by modulating let-7e-5p and miRNA-18a-5p expression in endothelial cells. Arterioscler Thromb Vasc Biol. 2021;41(6):e325–37. https://doi.org/10.1161/ATVBAHA.121.316180.

    Article  CAS  PubMed  Google Scholar 

  14. Li B, Zhang T, Liu M, Cui Z, Zhang Y, Liu M, et al. RNA N6-methyladenosine modulates endothelial atherogenic responses to disturbed flow in mice. Elife. 2022. https://doi.org/10.7554/eLife.69906.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Dong G, Yu J, Shan G, Su L, Yu N, Yang S. N6-Methyladenosine Methyltransferase METTL3 Promotes Angiogenesis and Atherosclerosis by Upregulating the JAK2/STAT3 Pathway via m6A Reader IGF2BP1. Fronti Cell Dev Biol. 2021. https://doi.org/10.3389/fcell.2021.731810.

    Article  Google Scholar 

  16. Ge L, Wang J, Qi W, Miao HH, Cao J, Qu YX, et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab. 2008;7(6):508–19. https://doi.org/10.1016/j.cmet.2008.04.001.

    Article  CAS  PubMed  Google Scholar 

  17. Xie P, Jia L, Ma Y, Ou J, Miao H, Wang N, et al. Ezetimibe inhibits hepatic Niemann-Pick C1-Like 1 to facilitate macrophage reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol. 2013;33(5):920–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Wang Y, Tang W, Yang P, Shin H, Li Q. Hepatic NPC1L1 promotes hyperlipidemia in LDL receptor deficient mice. Biochem Biophys Res Commun. 2018;499(3):626–33.

    Article  CAS  PubMed  Google Scholar 

  19. Davis HR Jr, Hoos LM, Tetzloff G, Maguire M, Zhu LJ, Graziano MP, et al. Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/- mice. Arterioscler Thromb Vasc Biol. 2007;27(4):841–9. https://doi.org/10.1161/01.ATV.0000257627.40486.46.

    Article  CAS  PubMed  Google Scholar 

  20. Temel RE, Tang W, Ma Y, Rudel LL, Willingham MC, Ioannou YA, et al. Hepatic Niemann-Pick C1–like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Investig. 2007;117(7):1968–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Boucher P, Matz RL, Terrand J. atherosclerosis: gone with the Wnt? Atherosclerosis. 2020;301:15–22. https://doi.org/10.1016/j.atherosclerosis.2020.03.024.

    Article  CAS  PubMed  Google Scholar 

  22. Reustle A, Torzewski M. Role of p38 MAPK in atherosclerosis and aortic valve sclerosis. Int J Mol Sci. 2018;19(12):3761. https://doi.org/10.3390/ijms19123761.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Tong J, Flavell RA, Li H-B. RNA m6A modification and its function in diseases. Front Med. 2018;12(4):481–9.

    Article  PubMed  Google Scholar 

  24. Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117–20.

    Article  PubMed  Google Scholar 

  25. Liu Y, Luo G, Tang Q, Song Y, Liu D, Wang H, et al. Methyltransferase-like 14 silencing relieves the development of atherosclerosis via m(6)A modification of p65 mRNA. Bioengineered. 2022;13(5):11832–43. https://doi.org/10.1080/21655979.2022.2031409.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Al Rifai M, Greenland P, Blaha MJ, Michos ED, Nasir K, Miedema MD, et al. Factors of health in the protection against death and cardiovascular disease among adults with subclinical atherosclerosis. Am Heart J. 2018;198:180–8.

    Article  PubMed  Google Scholar 

  27. Engel M, Eggert C, Kaplick PM, Eder M, Röh S, Tietze L, et al. The role of m6A/m-RNA methylation in stress response regulation. Neuron. 2018;99(2):389–403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Li H-B, Tong J, Zhu S, Batista PJ, Duffy EE, Zhao J, et al. m6A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. Nature. 2017;548(7667):338–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Chien CS, Li JY, Chien Y, Wang ML, Yarmishyn AA, Tsai PH, et al. METTL3-dependent N(6)-methyladenosine RNA modification mediates the atherogenic inflammatory cascades in vascular endothelium. Proc Natl Acad Sci U S A. 2021. https://doi.org/10.1073/pnas.2025070118.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Wang L-J, Song B-L. 2012 Niemann Pick C1-Like 1 and cholesterol uptake. Biochimica et Biophysica Acta (BBA)-Molecular Cell Biol Lipids. 2012;1821(7):964–72.

    Article  CAS  Google Scholar 

  31. Investigators MIGC. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371(22):2072–82.

    Article  Google Scholar 

  32. Yamamoto H, Yamanashi Y, Takada T, Mu S, Tanaka Y, Komine T, et al. Hepatic expression of Niemann-Pick C1-Like 1, a cholesterol reabsorber from bile, exacerbates western diet-induced atherosclerosis in LDL receptor mutant mice. Mol Pharmacol. 2019;96(1):47–55. https://doi.org/10.1124/mol.119.115840.

    Article  CAS  PubMed  Google Scholar 

  33. Liu H, Liu J, Liu Z, Wang Q, Liu J, Feng D, et al. Lycopene reduces cholesterol absorption and prevents atherosclerosis in ApoE(-/-) mice by downregulating HNF-1alpha and NPC1L1 expression. J Agric Food Chem. 2021;69(35):10114–20. https://doi.org/10.1021/acs.jafc.1c03160.

    Article  CAS  PubMed  Google Scholar 

  34. Simion V, Zhou H, Pierce JB, Yang D, Haemmig S, Tesmenitsky Y, et al. LncRNA VINAS regulates atherosclerosis by modulating NF-kappaB and MAPK signaling. JCI Insight. 2020. https://doi.org/10.1172/jci.insight.140627.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Lu S, Luo Y, Zhou P, Yang K, Sun G, Sun X. Ginsenoside compound K protects human umbilical vein endothelial cells against oxidized low-density lipoprotein-induced injury via inhibition of nuclear factor-kappaB, p38, and JNK MAPK pathways. J Ginseng Res. 2019;43(1):95–104. https://doi.org/10.1016/j.jgr.2017.09.004.

    Article  PubMed  Google Scholar 

  36. Gong L, Lei Y, Liu Y, Tan F, Li S, Wang X, et al. Vaccarin prevents ox-LDL-induced HUVEC EndMT, inflammation and apoptosis by suppressing ROS/p38 MAPK signaling. Am J Translat Res. 2019;11(4):2140.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Surgery, Shaanxi Provincial People’s Hospital, Xi’an, 710068, Shaanxi, China

    Guoan Zhang & Xuewen Li

  2. Shaanxi Provincial Key Laboratory of Infection and Immune Diseases, Shaanxi Provincial People’s Hospital, 256 West Youyi Road, Xi’an, 710068, Shaanxi, China

    Xiaoyan Huang

Authors
  1. Guoan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xuewen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaoyan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

GZ performed the experiments and prepared the manuscript; XH designed the study; XL analyzed the data and prepared the figures.

Corresponding author

Correspondence to Xiaoyan Huang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the Ethics Committee of Shaanxi Provincial People’s Hospital. All animal experiments were in accordance with the guide for the care and use of laboratory animals established by United States National Institutes of Health (Bethesda, MD, USA).

Additional information

Responsible Editor: John Di Battista.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 1849 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, G., Li, X. & Huang, X. m6A-related bioinformatics analysis and functional characterization reveals that METTL3-mediated NPC1L1 mRNA hypermethylation facilitates progression of atherosclerosis via inactivation of the MAPK pathway. Inflamm. Res. 72, 429–442 (2023). https://doi.org/10.1007/s00011-022-01681-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-022-01681-0

Keywords

Search

Navigation